AFAlice Ferretti

Alice Ferretti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alice Ferretti has a total of 206 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Optimal acquisition timing for perfusion imaging in dual-phase amyloid-PET: a within-patient list-mode comparison of 5-minute versus 10-minute protocols

    by Anna Margherita Maffione, Alice Ferretti, Paola Bartoletti, Lara Pavan, Arianna Massaro, Sotirios Chondrogiannis, Andrea Osele, Marcello Gava, Maria Cristina Marzola

  • Safire CT iterative reconstruction protocol to reduce patient effective dose on PET/CT examinations

    by Alice Ferretti, Sotirios Chondrogiannis, Jlenia Peretto, Anna Margherita Maffione, Paola Bartoletti, Luca Urso, Luigi Manco, Marcello Gava, Maria Cristina Marzola


  • Open Access

    Detection and Imaging with Leak Microstructures

    by Mariano Lombardi, Gianfranco Prete, Giovanni Balbinot, Alice Ferretti, Giuseppe Galeazzi, Andrea Battistella

    Results obtained with a new, very compact detector for imaging with a matrix of leak microstructures (LM) are reported. Spatial linearity and spatial resolution obtained by scanning and the detection of alpha particles with 100% efficiency, when compared with a silicon detector, are stressed. Preliminary results obtained in detecting single electrons emitted by the heated filament (Ec < 1 eV) at 1–3 mbar of propane are reported.

  • A new mobile self-dispensing and administering system for 18 F-FDG: evaluation of operator dose reduction

    by Alice Ferretti, Arianna Massaro, Stella Gusella, Lucia Rampin, Anna Margherita Maffione, Sotirios Chondrogiannis, Maria Cristina Marzola, Gaia Grassetto, Roberto Delgado-Bolton, Domenico Rubello, et al.

    Purpose: Recently new mobile systems for dispensing positron emitters have been produced, designed to guarantee dispensing cycles in an aseptic environment. The aim of the present work was to assess the advantage of one of these systems in radiation protection of operators in clinical settings. Methods: Recently, in our centre the new self-dispensing system named KARL 100 by Tema Sinergie was adopted for 18 F-FDG radiopharmaceuticals. The system is associated with an automatic Rad-inject infuser. The system that was previously used was a fixed isolator NMC DSI (Tema Sinergie), equipped with a μ DDS-An activity fractioning system, together with a pneumatic post for the syringe delivery. The dosimetric evaluations on both systems were carried out through environmental measurements with an ionisation chamber and with the use of personal dosimeters. Results: The operations of preparation and administration of 18 F-FDG dose to the patient, with the use of Karl 100 + RadInject, involve exposures much lower than those obtained by the fixed isolator. The average body exposure of the technician was reduced by 31%, and for the physician by 77%. On the extremities, the equivalent dose to the hands of the technician was reduced by 78%, and for the physician by 96%. Also the additional dosimeters worn by the technician confirmed the estimated environmental assessments. Conclusions: The exposures of the working personnel were significantly reduced with the introduction of the new KARL 100 system.


  • How to harmonize SUVs obtained by hybrid PET/CT scanners with and without point spread function correction

    by Alice Ferretti, Sotirios Chondrogiannis, Lucia Rampin, Elena Bellan, Maria Cristina Marzola, Gaia Grassetto, Stella Gusella, Anna Margherita Maffione, Marcello Gava, Domenico Rubello

    State of the art point-spread function (PSF) corrections implemented in positron emission tomography/computed tomography (PET/CT) reconstruction improved image quality and diagnostic performance but caused an increase in the standardized uptake value (SUV) compared to a conventional OSEM reconstruction system. The EANM suggested one produce two reconstructions, one optimised for maximum lesion detection and one for semi-quantitative analysis. In this work we investigated an alternative methodology, using a single reconstruction data set together with a post-reconstruction algorithm for SUV harmonization. Data acquisition was performed on a Siemens Biograph mCT system equipped with lutetium oxyorthosilicat crystals, PSF and time-of-flight algorithms and on a General Electric Discovery STE system equipped with BGO crystals. Both a EANM double reconstruction method and a dedicated post-reconstruction algorithm (marketed as EQ-filter) were tested to harmonize the quantitative values of the two PET/CT scanners. For phantom measurements we used a NEMA IQ phantom and a Jaszczak cylindrical phantom equipped with small spheres (lesion to background ratios of 8:1 and 4:1). Several different reconstruction settings were tested in order to provide a general methodology. Data obtained by phantom measurements were validated on seven oncologic patients who performed a one-bed extra acquisition on a different scanner. The evaluation regarded 39 small lesions (diameters: 0.3–2.6 cm) and was performed by two experienced nuclear medicine physicians. The SUV recoveries measured with the PSF reconstruction exceeded those obtained by the OSEM reconstruction with deviations ranging from 16% to 150%. These discrepancies resulted below 7% applying the optimized value of the EQ.filter or the double-reconstruction methods. For each reconstruction setting the optimal value of the EQ.filter was identified in order to minimize these discrepancies. Patient data, analyzed by Wilcoxon statistical test, confirmed and validated phantom measurements. EQ.filter can harmonize SUV values between different PET/CT scanners using a single reconstruction optimized to maximum lesion detectability. In this way, the second reconstruction proposed by EANM/EARL is avoided.


  • Influence of PEG coating on the biodistribution and tumor accumulation of pH-sensitive liposomes

    by Shirleide Santos Nunes, Renata Salgado Fernandes, Carolina Henriques Cavalcante, Isabela da Costa César, Elaine Amaral Leite, Sávia Caldeira Araújo Lopes, Alice Ferretti, Domenico Rubello, Danyelle M. Townsend, Mônica Cristina de Oliveira, et al.

    Liposomes are lipid vesicles widely used as nanocarriers in targeted drug delivery systems for therapeutic and/or diagnostic purposes. A strategy to prolong the blood circulation time of the liposomes includes the addition of a hydrophilic polymer polyethylene glycol (PEG) moiety onto the surface of the vesicle. Several studies claim that liposome PEGylation by a single chain length or a combination of PEG with different chain lengths may alter the liposomes’ pharmacokinetic properties. Therefore, the purpose of this study was to evaluate the influence of PEG on the biodistribution of pH-sensitive liposomes in a tumor-bearing animal model. Three liposomal formulations (PEGylated or not) were prepared and validated to have a similar mean diameter, monodisperse distribution, and neutral zeta potential. The pharmacokinetic properties of each liposome were evaluated in healthy animals, while the biodistribution and scintigraphic images were evaluated in tumor-bearing mice. High tumor-to-muscle ratios were not statistically different between the PEGylated and non-PEGylated liposomes. While PEGylation is a well-established strategy for increasing the blood circulation of nanostructures, in our study, the use of polymer coating did not result in a better in vivo profile. Further studies must be carried out to confirm the feasibility of the non-PEGylated pH-sensitive liposomes for tumor treatment.


  • Sentinel lymph node biopsy in small papillary thyroid cancer. A review on novel surgical techniques

    by Ludovico Maria Garau, Domenico Rubello, Alice Ferretti, Giuseppe Boni, Duccio Volterrani, Gianpiero Manca

    Sentinel lymph node biopsy (SNB) in patients with papillary thyroid carcinoma (PTC) and negative for clinically neck lymph node metastatic involvement (N0) has emerged as a promising minimally invasive procedure to detect metastatic nodes.


  • FDG PET/CT in Aortic Valve Bioprosthesis Infection

    by Lucia Rampin, Alice Ferretti, Maria Cristina Marzola, Lolita Sasset, Sotirios Chondrogiannis, Anna Maria Cattelan, Domenico Rubello, Patrick M. Colletti

    A 62-year-old man presented with persistent fever, weakness, and retrosternal pain 3 years after aortic valve bioprosthesis (AVR). His white blood cell count was 11,000/μL and C-reactive protein was 13.6 mg/dL. Consecutive blood cultures isolated Staphylococcus epidermidis and capitis. Transesophageal echocardiography demonstrated small aortic valve prosthesis vegetation. 18F-FDG PET/CT revealed prominent AVR activity, SUVmax = 12.2. He was treated with daptomycin, meropenem, and gentamicin for 1 month and followed by daptomycin and carbapenem for 3 months. Follow-up 18F-FDG PET/CT at 6 months demonstrated complete clearing of AVR activity associated with full asymptomatic recovery.


  • Catecholamine-Induced Chest Pain Mimicking Infarction Due to an MIBG-Negative and DOPA-Positive Succinate Dehydrogenase Syndrome Subunit B–Related Pheochromocytoma

    by Alberto Mazza, Alice Ferretti, Antonella Paola Sacco, Domenico Rubello, Patrick M. Colletti

    This 16-year-old boy presented with acute retrosternal pain possibly representing acute myocardial infarction. Cardiac enzymes were within reference ranges. There were marked increases in metanephrine to 3299 μg/24 h (reference, <400 μg/24 h), normetanephrine to 1309 μg/24 h (reference, 0–390 μg/24 h), and chromogranin A to 1605 ng/mL (reference, 0–150 μg/24 h). An incidental left adrenal mass was found during CTPA performed to exclude pulmonary embolism. 123I-MIBG scintigraphy was negative, and genetic screening detected SDHB (succinate dehydrogenase syndrome subunit B) gene mutation. Based on the gene mutation, 18F-DOPA PET/CT was performed, confirming a left-sided pheochromocytoma.

  • Technetium-99 m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo

    by Liziane O.F. Monteiro, Renata S. Fernandes, Luciano C. Castro, Valbert N. Cardoso, Mônica C. Oliveira, Danyelle M. Townsend, Alice Ferretti, Domenico Rubello, Elaine A. Leite, André L.B. de Barros